Can a single dose ease fragile x? new trial tests three drugs

NCT ID NCT05418049

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of baclofen, roflumilast, or memantine can improve brain activity and symptoms in adults with Fragile X syndrome. Forty-five participants aged 18 to 45 will receive each drug or a placebo in separate sessions. The main goal is to measure changes in brain waves using EEG, along with clinician and caregiver ratings of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

baclofen, roflumilast, memantine

What this could lead to

If successful, this could point toward a short-term treatment to ease certain symptoms of Fragile X syndrome.

What could go wrong

This is an early phase 2 trial with only 45 participants, testing single doses. It may not show clear benefits, and results may not apply to long-term use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fragile X syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States